The effect of CVMSCs on MDA-MB231 cells proliferation was assessed in vitro over 50 hour. C is MDA-MB231, and V is CVMSC. MDA-MB231 cells were pretreated with CVMSCs through a transwell membrane. The reduction in the proliferative capacity of MDA-MB231 induced by CVMSCs was statistically significant (P.0001) compared to the control; untreated MDA-MB231). Each experiment was done in quadruplicate.</p
<p>Cells were treated with 3.2 or 4 µM MSA, 10 nM paclitaxel, or the combinations for 72 hr. Live ce...
<p>Primary astrocytes (3×10<sup>4</sup>), were activated with PMA 100 nM and simultaneously treated ...
<p><b>A. MOVAS cell proliferation by XTT.</b> MOVAS cells were seeded in 96-well plate and incubated...
The effect of CVMSCs on MDA-MB231 cells proliferation, in vitro, over 50 hour period (data represent...
Where the control is C (MDA-MB231), and V is human placental chorionic villi derived MSC. The reduct...
Two-way ANOVA analyzed the two treated groups; 1:1 and 1:3 and each group was compared to the contro...
<p>(A) BMEC-1 proliferation curve. To analyze the effect of the BM supernatant fluid from MDS patien...
<p>(A) Cell growth curve was evaluated using trypan blue staining to measure viable cells at 24, 48 ...
<p>(a) VSMCs were cultured in 96-well plates and incubated with 0, 1, 5, 10, 20 or 100 ug/ml concent...
Cell proliferation was evaluated by MTS assay and expressed as percentage value with respect to cont...
<p>(A) The presence of MSCs reduces the expansion of Vδ2+ cells. Representative flow cytometric anal...
<p>Bar graphs represent folds of controls (CL) SMCs, mean ± standard error of the mean (SEM) of 5 in...
<p>MDA-MB-231 cells treated with control or Monad siRNA (A) or overexpressing GFP or Monad (B) were ...
<p>(A) Representative flow cytometry plots of CD45+ leukocytes from diaphragms of vehicle- and CVC-t...
<p>αMEM containing 10% FBS was included in the study as a positive control. 72 h later, the media we...
<p>Cells were treated with 3.2 or 4 µM MSA, 10 nM paclitaxel, or the combinations for 72 hr. Live ce...
<p>Primary astrocytes (3×10<sup>4</sup>), were activated with PMA 100 nM and simultaneously treated ...
<p><b>A. MOVAS cell proliferation by XTT.</b> MOVAS cells were seeded in 96-well plate and incubated...
The effect of CVMSCs on MDA-MB231 cells proliferation, in vitro, over 50 hour period (data represent...
Where the control is C (MDA-MB231), and V is human placental chorionic villi derived MSC. The reduct...
Two-way ANOVA analyzed the two treated groups; 1:1 and 1:3 and each group was compared to the contro...
<p>(A) BMEC-1 proliferation curve. To analyze the effect of the BM supernatant fluid from MDS patien...
<p>(A) Cell growth curve was evaluated using trypan blue staining to measure viable cells at 24, 48 ...
<p>(a) VSMCs were cultured in 96-well plates and incubated with 0, 1, 5, 10, 20 or 100 ug/ml concent...
Cell proliferation was evaluated by MTS assay and expressed as percentage value with respect to cont...
<p>(A) The presence of MSCs reduces the expansion of Vδ2+ cells. Representative flow cytometric anal...
<p>Bar graphs represent folds of controls (CL) SMCs, mean ± standard error of the mean (SEM) of 5 in...
<p>MDA-MB-231 cells treated with control or Monad siRNA (A) or overexpressing GFP or Monad (B) were ...
<p>(A) Representative flow cytometry plots of CD45+ leukocytes from diaphragms of vehicle- and CVC-t...
<p>αMEM containing 10% FBS was included in the study as a positive control. 72 h later, the media we...
<p>Cells were treated with 3.2 or 4 µM MSA, 10 nM paclitaxel, or the combinations for 72 hr. Live ce...
<p>Primary astrocytes (3×10<sup>4</sup>), were activated with PMA 100 nM and simultaneously treated ...
<p><b>A. MOVAS cell proliferation by XTT.</b> MOVAS cells were seeded in 96-well plate and incubated...